Who is sponsoring NCT03214302?

NCT03214302 is sponsored by Beijing Ditan Hospital.

What drugs are being tested in NCT03214302?

Interventions in NCT03214302: Tenofovir Disoproxil Fumarate.

What condition does NCT03214302 study?

NCT03214302 studies Chronic Hepatitis B.

Is NCT03214302 still recruiting?

NCT03214302 is currently status unknown. Last updated 13 July 2017.

Last reviewed 2017-07-13 · How we verify

NCT03214302

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Incidence of Postpartum Hepatitis in Pregnant Women With Chronic Hepatitis B Virus Infection

Status unknown NA Last updated 13 July 2017

What this trial tests

NA trial testing Tenofovir Disoproxil Fumarate in Chronic Hepatitis B in 560 participants. Status unknown.

Timeline

1 January 2017

Primary endpoint
30 December 2019

30 December 2019

Quick facts

Lead sponsor	Beijing Ditan Hospital
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	560
Start date	1 January 2017
Primary completion	30 December 2019
Estimated completion	30 December 2019
Sites	1 location across China

Drugs / interventions tested

Tenofovir Disoproxil Fumarate — full drug profile →

Conditions studied

Chronic Hepatitis B — all drugs for Chronic Hepatitis B →

Sponsor

Beijing Ditan Hospital

Who can join

Adults 20 to 35, female only, with Chronic Hepatitis B. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The majority of childbearing age women with hepatitis B virus infection were still in the immune tolerance period. Our recent research had shown that most puerperae after delivery had elevated ALT level. However, there is no withdrawal time recommendations after childbirth at present.Through the study of hepatitis occurrence after delivery and drug withdrawal, the investigators explore the withdrawal time of antiviral treatment during pregnancy.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Effects of antiviral therapy and drug withdrawal on postpartum hepatitis in pregnant women with chronic HBV infection.
Li M, Sun F, Bi X, Lin Y, et al · · 2023 · cited 8× · PMID 36109430 · DOI 10.1007/s12072-022-10412-w
Effect of Antiviral Therapy During Pregnancy on Natural Killer Cells in Pregnant Women With Chronic HBV Infection.
Wang F, Xie S, Ran C, Hao H, et al · · 2022 · cited 8× · PMID 35677040 · DOI 10.3389/fimmu.2022.893628
The relation of the frequency and functional molecules expression on plasmacytoid dendritic cells to postpartum hepatitis in women with HBeAg-positive chronic hepatitis B virus infection.
Wang F, Song M, Hu Y, Yang L, et al · · 2022 · cited 2× · PMID 36439153 · DOI 10.3389/fimmu.2022.1062123

Verify or expand the search:

Other trials of Tenofovir Disoproxil Fumarate

Trials testing the same drug.

NCT05652478 — Early Metabolic Effects of Antiretroviral Drugs in Healthy volUnteers: a Phase 2 Randomized Study · Phase 2 · recruiting
NCT06586983 — Decentralization of Hepatitis B Care in Sub-Saharan Africa: a Pilot Program in Ethiopia · recruiting
NCT06356662 — Tenofovir Disoproxil Fumarate in the Treatment of Parkinson's Disease · Phase 1 · recruiting
NCT04862975 — Pharmacokinetics of Antiretroviral Drugs in Lactating Women and Breastmilk Fed Infants Under 6 Months of Age in Botswana · completed
NCT06573190 — Liver Status and Presence of MASLD/MASH in Patients With Chronic Hepatitis B · completed

Other recruiting trials for Chronic Hepatitis B

Currently open trials in the same condition.

NCT07275918 — SA1211 Injection Phase 1 Study · Phase 1 · recruiting
NCT04843852 — TLR-9 Adjuvanted Vaccination for Chronic Hepatitis B · Phase 1 · recruiting
NCT07135349 — A Phase II Clinical Study of BW-20507 in Combination With PEG-IFNα for the Treatment of Hepatitis B · Phase 2 · active not recruiting
NCT07307586 — A Small Sample Prospective Clinical Study of Azvudine Tablets to Promote Clinical Cure in Patients With Chronic Hepatiti · Phase 3 · recruiting
NCT07246889 — Study of AHB-137 in Participants With Chronic Hepatitis B (CHB) Treated With Nucleos(t)Ide Analogues (NAs)(AUSHINE) · Phase 3 · active not recruiting

Other Beijing Ditan Hospital trials

Trials by the same sponsor.

NCT06642740 — Study on the Efficacy and Safety of Avatricopal in Patients With CLD Complicated With Thrombocytopenia · enrolling by invitation
NCT06777173 — Clinical Study of Antiviral Therapy Combined With Novel Immunotherapy for CHB in Adults · NA · enrolling by invitation
NCT05929963 — Observational Study of the Interaction Between Hepatitis C Virus Infection and Pregnancy · unknown
NCT05812612 — UDCA in the Treatment of COVID-19 Infection and Its Clinical Prognosis in Patients With Autoimmune Liver Disease · unknown
NCT05765279 — A Study to Assess the Efficacy of HH-120 Nasal Spray for Prevention of SARS-CoV-2 Infection in Adult Close Contacts of I · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03214302 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Beijing Ditan Hospital
Last refreshed: 13 July 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03214302.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing